GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (CHIX:SANNz) » Definitions » Enterprise Value

Santhera Pharmaceuticals Holding AG (CHIX:SANNZ) Enterprise Value : CHF121.9 Mil (As of Dec. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Santhera Pharmaceuticals Holding AG's Enterprise Value is CHF121.9 Mil. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was CHF80.5 Mil. Therefore, Santhera Pharmaceuticals Holding AG's EV-to-EBIT ratio for today is 1.51.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Santhera Pharmaceuticals Holding AG's Enterprise Value is CHF121.9 Mil. Santhera Pharmaceuticals Holding AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was CHF84.5 Mil. Therefore, Santhera Pharmaceuticals Holding AG's EV-to-EBITDA ratio for today is 1.44.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Santhera Pharmaceuticals Holding AG's Enterprise Value is CHF121.9 Mil. Santhera Pharmaceuticals Holding AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was CHF113.6 Mil. Therefore, Santhera Pharmaceuticals Holding AG's EV-to-Revenue ratio for today is 1.07.


Santhera Pharmaceuticals Holding AG Enterprise Value Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Enterprise Value Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 200.13 337.21 783.44 1,055.04 103.20

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 861.07 1,055.04 115.60 103.20 108.76

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Enterprise Value

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Enterprise Value falls into.



Santhera Pharmaceuticals Holding AG Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Santhera Pharmaceuticals Holding AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Santhera Pharmaceuticals Holding AG's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG  (CHIX:SANNz) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Santhera Pharmaceuticals Holding AG's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=121.862/80.479
=1.51

Santhera Pharmaceuticals Holding AG's current Enterprise Value is CHF121.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was CHF80.5 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Santhera Pharmaceuticals Holding AG's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=121.862/84.471
=1.44

Santhera Pharmaceuticals Holding AG's current Enterprise Value is CHF121.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was CHF84.5 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Santhera Pharmaceuticals Holding AG's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=121.862/113.589
=1.07

Santhera Pharmaceuticals Holding AG's current Enterprise Value is CHF121.9 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was CHF113.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG Enterprise Value Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG Headlines

No Headlines